Research Paper Volume 14, Issue 1 pp 272—285
The effects of metformin and alendronate in attenuating bone loss and improving glucose metabolism in diabetes mellitus mice
- 1 Department of Orthopedics, The Shanghai Tenth People’s Hospital of Tongji University, Shanghai, PR China
- 2 Department of Orthopedics, Qinghai Provincial People’s Hospital, Xining, Qinghai, PR China
- 3 Department of Dermatology, The First People’s Hospital of Xuzhou, Xuzhou, Jiangsu 221002, PR China
- 4 Department of Radiology, Beijing Jishuitan Hospital, Beijing 10035, PR China
- 5 Department of Rheumatology and Immunology, The First People’s Hospital of Xuzhou, Xuzhou, Jiangsu 221002, PR China
Received: August 9, 2021 Accepted: November 24, 2021 Published: January 14, 2022
https://doi.org/10.18632/aging.203729How to Cite
Copyright: © 2022 Zhou et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Background: To explore the anti-osteoporosis and anti-diabetes effects and potential underlying mechanisms of treatment with metformin and alendronate in diabetes mellitus mice.
Methods: Eight-week-old C57 BL/KS db/db and db/+ female mice were evaluated according to the following treatment group for 12 weeks: control group, diabetes mellitus group, diabetes mellitus with metformin group, diabetes mellitus with Alendronate group, diabetes mellitus with metformin plus alendronate group. Glucose level, glucose tolerance test, bone mineral density, bone microarchitecture, bone histomorphometry, serum biomarkers, and qPCR analysis.
Results: Combined metformin and alendronate can improve progression in glucose metabolism and bone metabolism, including blood glucose levels, blood glucose levels after 4 and 16 hours fasting, glucose tolerance test results, insulin sensitivity and reduces bone loss than the diabetes group. The use of alendronate alone can increase significantly serum glucagon-like peptide-1 levels than the diabetes group. The use of metformin alone can improve bone microstructure such as Tb.Sp and Tb.N of spine in diabetic mice.
Conclusion: The combined use of alendronate and metformin has an anti-diabetes and anti-osteoporotic effect compared with diabetic mice, but they appear to act no obvious synergistically between alendronate and metformin.